PELL Bio-Med Technology Co. Ltd. (6949.TW)
TWD 83.5
(0.6%)
TWD 83.5
(0.6%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -179.83 Million | -155.67 Million | -108.51 Million |
| Net Income | -398.75 Million | -230.13 Million | -188.95 Million |
| Depreciation & Amortization | 45.61 Million | 31.04 Million | 30.16 Million |
| Deferred income taxes | - | - | - |
| Stock-based compensation | 143.06 Million | 46.68 Million | 24.96 Million |
| Change in working capital | 33.2 Million | -2.18 Million | 25.13 Million |
| Other non-cash items | 230.61 Million | 101.46 Million | 76.27 Million |
| Investing Cash Flow | -419.63 Million | -535.96 Million | 83.9 Million |
| Investments in PPE | -16.48 Million | -8.49 Million | -14.47 Million |
| Acquisitions | 3.49 Million | 14.99 Million | 48 Thousand |
| Investment purchases | -1.44 Billion | -778.3 Million | - |
| Sales/Maturities of investments | 1.04 Billion | 242.3 Million | 100 Million |
| Other Investing Activities | -4.48 Million | -6.46 Million | -1.67 Million |
| Financing Cash Flow | 594.74 Million | 748.26 Million | -4.56 Million |
| Debt repayment | -5.15 Million | -303 Thousand | -673 Thousand |
| Dividends payments | - | - | - |
| Common Stock Repurchased | -800 Thousand | - | - |
| Common Stock Issuance | 625.76 Million | 759.33 Million | 5.02 Million |
| Other Financing Activities | 620.76 Million | 14.99 Million | 5.02 Million |
| Accounts receivables | -1.52 Million | 4.14 Million | 7.12 Million |
| Accounts payables | 1.42 Million | 2.42 Million | -5.07 Million |
| Inventory | 817 Thousand | -343 Thousand | 7.14 Million |
| Other working capital | 32.49 Million | -8.4 Million | 15.93 Million |
| Cash at beginning of period | 172.4 Million | 115.78 Million | 144.95 Million |
| Cash at end of period | 167.67 Million | 172.4 Million | 115.78 Million |
| Capital Expenditure | -16.48 Million | -8.49 Million | -14.47 Million |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | -4.72 Million | 56.62 Million | -29.17 Million |
| Free Cash Flow | -196.32 Million | -164.17 Million | -122.98 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -101.54 Million | -85.29 Million | -99.16 Million | -398.75 Million | -119.01 Million | -122.62 Million |
| Depreciation & Amortization | 11.75 Million | 11.68 Million | 11.34 Million | 45.61 Million | 11.33 Million | 11.52 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 16.1 Million | 24.28 Million | 27.38 Million | 143.06 Million | 57.24 Million | 54.27 Million |
| Change in working capital | 33.26 Million | -3.22 Million | 7.72 Million | 33.2 Million | 13.2 Million | 12.97 Million |
| Other non-cash items | 36.89 Million | 45.06 Million | -2.04 Million | 230.61 Million | -1.19 Million | 75.17 Million |
| Investing Cash Flow | 410.63 Million | -315.75 Million | -488.36 Million | -419.63 Million | 76.16 Million | -13.57 Million |
| Investments in PPE | -4.16 Million | -5.15 Million | -7.88 Million | -16.48 Million | -2.78 Million | -4.74 Million |
| Acquisitions | 109.8 Million | 1 Million | - | 3.49 Million | - | - |
| Investment purchases | -215 Million | -700 Million | -620.75 Million | -1.44 Billion | -822.54 Million | 529.86 Million |
| Sales/Maturities of investments | 520 Million | 388.4 Million | 141.5 Million | 1.04 Billion | 899.07 Million | -536.5 Million |
| Other Investing Activities | -6.41 Million | -2.18 Million | -1.23 Million | -4.48 Million | -1.06 Million | -2.18 Million |
| Financing Cash Flow | 6.35 Million | 305.18 Million | 585.88 Million | 594.74 Million | 20.32 Million | -1.21 Million |
| Debt repayment | -6.34 Million | -5.96 Million | -6.29 Million | -5.15 Million | -6.43 Million | -56 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -800 Thousand | -800 Thousand | - | - |
| Common Stock Issuance | 12.7 Million | 311.15 Million | 592.98 Million | 625.76 Million | 26.75 Million | 5.25 Million |
| Other Financing Activities | 122.5 Million | 311.15 Million | 592.98 Million | 620.76 Million | 26.75 Million | - |
| Accounts receivables | -271 Thousand | 2.89 Million | -3.39 Million | -1.52 Million | -347 Thousand | -419 Thousand |
| Accounts payables | 3.11 Million | -2.15 Million | - | 1.42 Million | - | 270 Thousand |
| Inventory | -1.88 Million | 1 Million | -365 Thousand | 817 Thousand | -682 Thousand | 1.73 Million |
| Other working capital | 32.3 Million | -4.97 Million | 13.21 Million | 32.49 Million | 9.14 Million | 11.38 Million |
| Cash at beginning of period | 103.7 Million | 167.67 Million | 123.13 Million | 172.4 Million | 64.02 Million | 123.23 Million |
| Cash at end of period | 478.5 Million | 103.7 Million | 167.67 Million | 167.67 Million | 123.13 Million | 64.02 Million |
| Capital Expenditure | -4.16 Million | -5.15 Million | -7.88 Million | -16.48 Million | -2.78 Million | -4.74 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 374.8 Million | -63.96 Million | 44.54 Million | -4.72 Million | 59.1 Million | -59.2 Million |
| Free Cash Flow | -46.35 Million | -58.54 Million | -60.85 Million | -196.32 Million | -40.17 Million | -49.16 Million |
HUG
0RP4
HPGLY
2127
JMART-R
PR1